Latest posts
-
David Baker on AI, open science, and building biotech startups
Our director recently share his thoughts on the impact of AI on life science startups. He spoke with Jenny Cronin, principal at the AI2 Incubator.
-
Our commitment to responsible AI development
To maximize the benefits and minimizing risks of AI for protein design, IPD director David Baker and scores of other senior scientists across 20 countries have signed a community agreement with ten actionable commitments and invited others in the field to join them. The Institute for Protein Design is playing…
-
From AI to anti-venom: Celebrating our women in science
To commemorate the International Day of Women and Girls in Science on February 11, we’re shining a spotlight on some of the extraordinary women we have had the privilege to work with.
-
David Baker and George Church call for enhanced controls on DNA synthesis
To maintain biosecurity in the age of AI, all synthesized DNA sequences should be screened and logged, according to two leading scientists. Such records could be decrypted and scrutinized in the event of a novel biological threat, a practice that may help deter the misuse of biodesign software. David Baker…
-
Nature: “Seven technologies to watch in 2024”
AI-enabled protein design is a technology area you’ll want to keep an eye on, according to Nature. With massive training datasets and ever more sophisticated deep-learning approaches, tools like our own RFdiffusion All-Atom are opening the door to custom enzymes, advanced biomaterials, and more. From Nature: Deep learning for protein…
-
Nanopore designers receive first commercialization grant
With support from the Washington Research Foundation, this project aims to create custom protein nanopores that can be integrated into semiconductor devices, unlocking the first direct interface between biology and electronics for multi-omics applications.
-
AI generates proteins with exceptional binding strengths
This advance could allow scientists to create cheaper alternatives to antibodies for disease detection and treatment. This week we report in Nature an AI-enabled advance in biotechnology with implications for drug development, disease detection, and environmental monitoring. Using a combination of traditional and deep learning based molecular design approaches, we’ve…
-
A new path to carbon storage
Our research shows that custom proteins can drive the growth of limestone-like minerals, a breakthrough that may one day help remove excess carbon from the environment.
-
AstraZeneca to buy Icosavax for $1.1B
Today we learned that Icosavax, a Seattle-based vaccine design company born from innovative research conducted here at the Institute for Protein Design, will be acquired by AstraZeneca in a deal worth up to $1.1 billion. “This is a significant moment for the UW School of Medicine, showcasing how fundamental research…
-
Introducing the Srivatsan Lab
We’re excited to announce a new partnership: the Srivatsan Lab has been named an Affiliate Lab of the Institute for Protein Design. This new lab is at the forefront of leveraging protein design and molecular sequencing to uncover the intricate dance between cells and the genes that guide their function.…